A new patient-reported outcome measure for symptom benefit with chemotherapy: the Measure of Ovarian Symptoms and Treatment concerns (MOST)

被引：0
|
作者：
King, M. T. [1 ,2 ]
Stockler, M. R. [3 ]
Butow, P. [1 ,2 ]
O'Connell, R. [3 ]
Voysey, M. [3 ]
Oza, A. M. [4 ]
Gillies, K. [3 ]
Donovan, H. S. [5 ]
Mercieca-Bebber, R. [1 ,2 ]
Martyn, J. [3 ]
Sjoquist, K. [3 ]
Friedlander, M. L. [3 ]
机构：
[1] Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia
[2] Univ Sydney, Psychooncol Cooperat Res Grp PoCoG, Sydney, NSW 2006, Australia
[3] Univ Sydney, ANZGOG & NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
[4] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[5] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2014年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCSM-0004
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [1] Validation of the measure of ovarian symptoms and treatment concerns (MOST), a patient-reported outcome measure (PROM) of symptom burden and subjective benefit with chemotherapy in recurrent ovarian cancer (ROC)
    King, Madeleine
    Stockler, Martin
    O'Connell, Rachel
    Joly, Florence
    Lanceley, Anne
    Hilpert, Felix
    Okamoto, Aikou
    Aotani, Eriko
    Pignata, Sandro
    Donnellan, Paul
    Oza, Amit
    Avall-Lundqvist, Elisabeth
    Berek, Jonathan
    Buizen, Luke
    Sjoquist, Katrin
    Gillies, Kim
    Butow, Phyllis
    Friedlander, Michael
    QUALITY OF LIFE RESEARCH, 2015, 24 : 22 - 23
  • [2] Development of the Measure of Ovarian Symptoms and Treatment Concerns Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer
    King, Madeleine T.
    Stockler, Martin R.
    Butow, Phyllis
    O'Connell, Rachel
    Voysey, Merryn
    Oza, Amit M.
    Gillies, Kim
    Donovan, Heidi S.
    Mercieca-Bebber, Rebecca
    Martyn, Julie
    Sjoquist, Katrin
    Friedlander, Michael L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (05) : 865 - 873
  • [3] Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
    King, Madeleine T.
    Stockler, Martin R.
    O'Connell, Rachel L.
    Buizen, Luke
    Joly, Florence
    Lanceley, Anne
    Hilpert, Felix
    Okamoto, Aikou
    Aotani, Eriko
    Bryce, Jane
    Donnellan, Paul
    Oza, Amit
    Avall-Lundqvist, Elisabeth
    Berek, Jonathan S.
    Sehouli, Jalid
    Feeney, Amanda
    Berton-Rigaud, Dominique
    Costa, Daniel S. J.
    Friedlander, Michael L.
    QUALITY OF LIFE RESEARCH, 2018, 27 (01) : 59 - 74
  • [4] Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
    Madeleine T. King
    Martin R. Stockler
    Rachel L. O’Connell
    Luke Buizen
    Florence Joly
    Anne Lanceley
    Felix Hilpert
    Aikou Okamoto
    Eriko Aotani
    Jane Bryce
    Paul Donnellan
    Amit Oza
    Elisabeth Avall-Lundqvist
    Jonathan S. Berek
    Jalid Sehouli
    Amanda Feeney
    Dominique Berton-Rigaud
    Daniel S. J. Costa
    Michael L. Friedlander
    Quality of Life Research, 2018, 27 : 59 - 74
  • [5] VALIDATION OF A PATIENT REPORTED OUTCOME MEASURE (PROM) OF OVARIAN CANCER SYMPTOMS AND TREATMENT RELATED CONCERNS (MOST-OSI) WITH CHEMOTHERAPY IN RECURRENT OVARIAN CANCER (ROC).
    King, M.
    Stockler, M.
    O'Connell, R.
    Joly, F.
    Lanceley, A.
    Hilpert, F.
    Okamoto, A.
    Aotani, E.
    Pignata, S.
    Donnellan, P.
    Oza, A.
    Avall-Lundqvist, E.
    Berek, J.
    Buizen, L.
    Sjoquist, K.
    Butow, P.
    Friedlander, M.
    Gillies, K.
    Martyn, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 457 - 458
  • [6] Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)
    Beesley, Vanessa L.
    Ross, Tanya L.
    King, Madeleine T.
    Campbell, Rachel
    Nagle, Christina M.
    Obermair, Andreas
    Grant, Peter
    DeFazio, Anna
    Webb, Penelope M.
    Friedlander, Michael L.
    GYNECOLOGIC ONCOLOGY, 2022, 164 (02) : 437 - 445
  • [7] Patient-reported cognitive symptoms and a patient-reported outcome measure of cognitive function in depression
    Forsyth, B.
    Fehnel, S.
    Danchenko, N.
    Francois, C.
    Brevig, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S229 - S230
  • [8] Development of a list of Symptom Items to Measure Patient-reported Outcome Symptoms of Hepatobiliary and Pancreatic Malignancies
    Zhan Yinxia
    Zhang Jingyu
    Shi Qiuling
    QUALITY OF LIFE RESEARCH, 2022, 31 : S142 - S143
  • [9] The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy
    Leah Kleinman
    Katy Benjamin
    Hema Viswanathan
    Maria Stoeckl Mattera
    Linda Bosserman
    Douglas W. Blayney
    Dennis A. Revicki
    Quality of Life Research, 2012, 21 : 1255 - 1266
  • [10] A patient-reported outcome measure for symptoms of AML/MDS.
    Williams, Loretta A.
    Garcia-Gonzalez, Araceli
    Ahaneku, Hycienth
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Shi, Qiuling
    Borthakur, Gautam
    Burger, Jan Andreas
    Jabbour, Elias
    Takahashi, Koichi
    Lin, Huei-Kai
    Limaye, Achala
    Cleeland, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345